Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | GRM5 | P41594 | 8/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12670077 | 0.89 | KDM4E (0.62) | KDM4EGRM5 | |
| SCHEMBL3329355 | 0.86 | KDM4E (0.76) | KDM4ETP53HDAC2MEN1KMT2A | |
| SCHEMBL3332938 | 0.84 | KDM4E (0.61) | KDM4EHDAC2MEN1KMT2AALDH1A1 | |
| SCHEMBL1905550 | 0.84 | GRM5 (0.62) | KDM4EGRM5PARP1 | |
| SCHEMBL3334496 | 0.79 | KDM4E (0.69) | KDM4EHDAC2MEN1KMT2AALDH1A1 | |
| SCHEMBL8235906 | 0.79 | KDM4E (0.69) | KDM4ETP53HDAC2MEN1KMT2A | |
| SCHEMBL3334438 | 0.79 | KDM4E (0.69) | KDM4EHDAC2MEN1KMT2AALDH1A1 | |
| SCHEMBL8167178 | 0.79 | KDM4E (0.69) | KDM4EHDAC2MEN1KMT2AALDH1A1 | |
| SCHEMBL3334279 | 0.79 | KDM4E (0.63) | KDM4EHDAC2MEN1KMT2AALDH1A1 | |
| SCHEMBL3329378 | 0.79 | KDM4E (0.63) | KDM4EHDAC2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | claimed |
| CN-101405266-A | Piperazines and piperidines as mGlur5 potentiators | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | CN | claimed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| EP-1979320-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007087135-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | claimed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | KDM4E 2334/4885GRM5 1/4885TP53 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.